Project Grant R01AI170894
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$782K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $299,969 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus. The goal is to confirm that vaccination with AGBR1 can protect against Chikungunya infection in mouse models, including both acute lethal infection and chronic disease manifestations like joint pain and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant to the University of Hawaii under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to understand the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines, including characterizing the antibody and T-cell immune responses induced in vaccine recipients. The proposed research aims to determine the baseline dengue virus serostatus...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,065,600.00 in funding to investigate the paradox of flavivirus antigenic non-reciprocity. The project, led by the University of Wisconsin-Madison, with sub-awards to the University of California, Berkeley and the University of Minnesota, aims to study how prior exposure to different flaviviruses, such as dengue and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to study the transmission dynamics of dengue and Zika viruses in northwestern coastal Ecuador. The $699,339 award will support parallel longitudinal cohorts to characterize the transmission dynamics at multiple geographic scales, focusing on the connections between human movement patterns, social networks, and...
This federal Project Grant award of $1,211,704.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate immune responses associated with severe disease in patients with primary dengue infection. The key research objectives are to: Determine differences in innate immune responses during severe primary versus secondary dengue infection. Evaluate differences in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $760,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis to develop recombinant enhanced antiviral sensors (REAVRS) that can broadly inhibit a range of viruses to control vector-borne and zoonotic viral diseases. The project aims to generate and optimize REAVR proteins, identify and characterize virus-inducible promoters in mosquito cells,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $737,761 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Pittsburgh to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (Tfh) cells to facilitate the differentiation of germinal center B cells into plasma cells, thereby enhancing the persistence and avidity of HIV...
This Project Grant award, totaling $874,372, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to unravel the molecular mechanisms by which Babesia parasites, which cause the tick-borne illness human babesiosis, interact with and communicate with their hosts. The goal is to leverage this knowledge to develop an effective and safe vaccine for human babesiosis....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $738,445 to Drexel University to develop a multivalent mRNA-based malaria vaccine. The key objectives are to: Optimize mRNA vaccine-induced antibody-mediated and cell-mediated protection against pre-erythrocytic stage Plasmodium falciparum parasites using a novel circumsporozoite protein (PfCSP) vaccine candidate....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,569 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant will fund research to characterize and optimize a novel genetic vaccine platform called PARVAX, with the goal of increasing its clinical acceptance and application for pandemic preparedness. Key objectives include investigating the mechanism behind the...